Immix Biopharma, Inc.IMMXNASDAQ
Loading
Free Cash Flow Growth AcceleratingAccelerating
Percentile Rank41
Studio
Year-over-Year Change

Year-over-year free cash flow growth rate

Percentile
P41
Within normal range
vs 5Y Ago
-0.2x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
PeriodValue
Q3 2025-15.46%
Q2 2025-210.20%
Q1 202511.62%
Q4 202453.96%
Q3 202419.53%
Q2 2024-29.65%
Q1 2024-53.45%
Q4 202313.92%
Q3 202311.09%
Q2 2023-68.04%
Q1 202346.41%
Q4 2022-166.94%
Q3 2022-167.33%
Q2 202263.40%
Q1 2022-34.17%
Q4 2021-2094.86%
Q3 202167.88%
Q2 202140.88%
Q1 2021-268.15%
Q4 2020321.60%
Q3 202070.84%
Q2 20200.00%
Q1 20200.00%